Back to Search Results
Walter G. Ross Chair in Clinical Research
Professor of Medicine
Office Phone: 202-795-2792
- MD (Honors), Albert Einstein College of Medicine, 1990
- BA, Yale College, 1992
- MSci, Harvard School of Public Health, 2001
Mardi Gomberg-Maitland, MD, MSc is a cardiologist and Professor of Medicine at the GW School of Medicine & Health Sciences. She is the Chief Clinical Research Officer for the SMHS Office of Clinical Research. She also serves as the Medical Director of the MFA/GWUH Pulmonary Hypertension Program and has built a comprehensive management program to include outpatient and inpatient diagnosis and treatment, noninvasive and invasive testing, and state of the art pulmonary hypertension medication options.
Dr. Gomberg-Maitland earned her Bachelor’s degree from Yale, completed her medical degree at Albert Einstein College of Medicine of Yeshiva University, with a special distinction for research in cardiovascular medicine. She served her residency in internal medicine at New York Presbyterian Hospital, Weill-Cornell Medical Center and was accepted for fellowship in cardiovascular diseases at Mount Sinai Medical Center. Dr. Gomberg-Maitland was also a visiting fellow in critical care medicine at the New York Presbyterian Hospital/Weill-Cornell Medical Center. She earned a Master’s degree in clinical epidemiology from the Harvard School of Public Health. She is boarded in Internal Medicine and Cardiovascular Disease and is licensed in Washington, DC and the Commonwealth of Virginia.
Dr. Gomberg-Maitland is an expert clinician and researcher in the field of pulmonary heart disease and complex heart failure. She has participated in dozens of multicenter, multinational research trials to explore new therapies for pulmonary arterial hypertension and pulmonary hypertension associated with left heart disease . Her research focus is in understanding the epidemiology of pulmonary hypertension and development of novel therapeutics and biomarkers.
Dr. Gomberg-Maitland is internationally known for her work, has had extensive grant funding and is extensively published with over 150 articles, abstracts, reviews and chapters. She has published in peer-reviewed journals, including the New England Journal of Medicine, Journal of the American College of Cardiology (JACC), JACC Heart Failure, Circulation, European Respiratory Journal, Chest, and the Journal of Heart and Lung Transplantation.
Post-Graduate Training:1996-1999 Residency, Internal Medicine, New York Presbyterian Hospital, Weill-Cornell, Medical Center, New York, NY
1999-2002 Fellowship, Cardiovascular Diseases, The Zena and Michael A. Wiener Cardiovascular Institute Mount Sinai Medical Center, New York, NY
2001-2002 Visiting Fellow, Critical Care Medicine, New York Presbyterian Hospital/Weill-Cornell Medical Center, New York, NY
2002-2003 Associate Director, Cardiac Care Unit, Mount Sinai Medical Center, New York, NY
2003-2004 Associate Director, Rush Heart Institute Center for Pulmonary Heart Disease, Rush University Medical Center, Chicago, IL
2004-2016 Director, Pulmonary Hypertension Center at the University of Chicago, University of Chicago Medical Center, Chicago, IL
2016-2018 Director Right Heart Failure, Heart Failure Preserved Ejection Fraction, and Cardio-Oncology Programs; Co-Director Pulmonary Vascular Disease, Inova Fairfax Heart and Vascular Institute, Falls Church, VA
2019- Director Pulmonary Hypertension Program, Medical Faculty Associates, George Washington University, Heart and Vascular Institute, Washington, DC
2023- Chief Clinical Research Officer, School of Medicine Health Sciences Office of Clinical Research, George Washington University, Washington, DC
2002-2003 Instructor of Medicine, Mount Sinai Medical Center, New York, NY
2003-2004 Assistant Professor of Medicine, Rush University Medical Center, Chicago, IL
2004-2009 Assistant Professor of Medicine University of Chicago Medical Center, Chicago, IL
2009-2016 Associate Professor of Medicine University of Chicago Medical Center, Chicago, IL
Joint appointment Committee on Clinical Pharmacology and Pharmacogenomics University of Chicago Medical Center, Chicago, IL
2016-2018 Professor of Medicine, Virginia Commonwealth University, Richmond, VA
2019- Professor of Medicine, George Washington University, Washington, DC (pending)
Licensure and Board Certification:
1999-2009 Diplomat American Board of Internal Medicine Certificate No. 189898
2012-2022 Medicine, Cardiovascular Disease
1999-2003 License No. 208532-1, State of New York
2003-2016 License No. 036-109605, State of Illinois
2018-2024 License No. 0202261135, State of Virginia
2019-2024 License No. MD046797, District of Columbia
1992 Yale University Varsity Letter- Swimming
1997 Society for the Advancement of Women’s Health Research Award: Oral Presentation “A Closer Look at Women with Asymptomatic Cardiac Ischemia.” Fifth Annual Congress on Women’s Health, Washington, DC, June 1997. J Women’s Health 1997; 6: 378.
1999 The David B. Skinner Award for Administrative Stewardship. For the medicine resident that most improved hospital services and patient care during training at New York Presbyterian Hospital.
2001 National Forum for Vascular Diseases, Coral Gables, Florida.
Selected to participate in interdisciplinary conference- One of 30 fellows selected based on research completed in vascular medicine.
2005 European Respiratory Society/American Thoracic Society Joint Research Seminar- invited attendee “Pulmonary Circulation: Molecular Determinants of Pulmonary Vascular Remodeling.
2006 National New Faces of PH Campaign: To increase awareness of PAH by media visibility campaign- TV appearance. (One of ten physicians chosen to participate.)
2006 The Rory Childers Teaching Award 2005-2006- The award is given by the cardiology fellows for to a member of the faculty for their teaching and support of the fellows.
2011 International Society of Heart and Lung Transplantation: abstract chosen as 1 of 2 featured abstracts for the final plenary session (out of 1260) based on merit and interest. First author on abstract was mentee, Richa Agarwal.
2012 Alfred Soffer Research Award Finalist; Two abstract awards given at the CHEST 2012 meeting for academic research based on the written abstract and the quality of the oral presentation. The awards are selected for outstanding original scientific research in honor of Alfred Soffer, MD, Master FCCP, who was Editor in Chief of CHEST from 1968-1993 and Executive Director of the ACCP from 1969-1992. (4 semifinalists)
2013 International Society of Heart and Lung Transplantation: abstract chosen as 1 of 2 featured abstracts for the final plenary session (out of 1347) based on merit and interest.
2012, 2013 Top reviewer for CHEST journal; there were less than 75 reviewers named.
2023 Best Research of the Year Department of Medicine: Awarded to the highest impact peer-reviewed research of the year, based on a number of potential factors including innovation, degree of scientific or public attention, impact on the field nationally/internationally and central involvement.
Centers and Institutes
2005-2006 Chair of SPORTIF Trial Writing Group, Gender Differences: Members: Nannette K Wenger, Jonathan L. Halperin, Palle Peterson, Jan Fenzi, Lars Frison, Maria Lengyel, and Annabelle S. Volgman.
2008-2012 Pulmonary Hypertension Association (PHA) Scientific Leadership Council Research Committee, chosen to help decide goals, implementation of funds for PHA research grants.
2010-2012 Co-Chair Registry Taskforce for International Society of Heart and Lung Transplantation, Pulmonary Hypertension Committee.
2010-present Steering Committee Member: ENTELLIGENCE- Young Investigators Program. The members serve as advisors to the program and review research proposals for grants in pulmonary vascular medicine.
2012-2014 Vice Chair, Pulmonary Hypertension Council- International, Society of Heart and Lung Transplantation
2014-2016 Chair, Pulmonary Hypertension Council: International Society of Heart and Lung Transplantation
2014-2016 Member, Rare Disease Advisory Panel for the Patient Centered Outcomes Research Institute (PCORI).
2015-present Member, NIH/NHLBI Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics: Study Monitoring Board: 4-physician advisory panel for multi-center network.
Clinical Education/Advisory Boards
2005 Member National Flolan Advisory Board, Dallas, TX.
2006 Pulmonary Arterial Hypertension Educational Council Meeting, AdVancing EduCation in PulmOnary HYpertension (VICTORY)- Panel of 14 PH physicians to create CME slides for planned National conferences and educational symposia.
2006-2007 Member National Flolan/Ambrisentan Advisory Board, Chicago IL.
2006-2007 American Heart Association Medical Leadership Committee, Go Red Campaign, Chicago, IL
2007-2009 American Heart Association Council on Cardiopulmonary, Peri-operative & Critical Care, Member Fall Program Committee
2008-2010 Pulmonary Vascular Research Institute Task Force on Databases, Co-Chair for International Database
2015-2017 Member, Pulmonary Hypertension Association Scientific Leadership Council Education Committee: To support Pulmonary Hypertension Association in its mission to advance pulmonary hypertension education by developing and reviewing medically accurate resources.
2015 Member, Pulmonary Hypertension Planning committee for Pulmonary Hypertension Fundamentals at PHA’s 2016 International PH Conference and Scientific Sessions
2016-present Member, Pulmonary Hypertension Association Scientific Leadership Council: To support Pulmonary Hypertension Association in its mission to advance pulmonary hypertension education, research, and patient support
2017-2020 Chair, Pulmonary Hypertension Association Scientific Leadership Council Education Committee: To support Pulmonary Hypertension Association in its mission to advance pulmonary hypertension education by developing and reviewing medically accurate resources.
2020-2021 Associate Chair for Pulmonary Vascular Disease (PAH & CTEPH). Standards and Guidelines (S&G) Committee. International Society of Heart and Lung Transplantation.
2020 Member, Program Committee, Pulmonary Vascular Disease. International Society of Heart and Lung Transplantation.
2020-2026 Member, School of Medicine and Health Sciences (SMHS) Research Committee. Reports and consults on basic, clinical, and translational research strategic goals for the SMHS.
2021-2023 Co-Chair, Endpoints and Trial Design Taskforce, Pulmonary Vascular Research Institute.
2021-2024 Member, Board of Directors. International Society of Heart and Lung Transplantation.
2021-Present Member, Finance Executive Committee. International Society of Heart and Lung Transplantation
2023-2026 Member, Program Committee, Pulmonary Vascular Disease, American College of Cardiology.
Professional Society Memberships:
American College of Chest Physicians- Fellow
American College of Physicians
American College of Cardiology- Women’s Section- Fellow
American Heart Association- Council on Cardiopulmonary Perioperative Critical Care-Fellow
American Society for Clinical Pharmacology and Therapeutics
American Thoracic Society
European Cardiology Society
European Respiratory Society
International Society of Heart and Lung Transplantation
Pulmonary Hypertension Association: Leadership
Pulmonary Vascular Research Institute- Fellow
Clinical Trial Oversight
2010-2016 Member, GRIPHON Trial Data Safety Monitoring Committee: 4 member panel to monitor the international trial of 670 patients, “A multi-center, double-blind, placebo-controlled phase 3 study to demonstrate the efficacy and safety of ACT-293987/selexipag in patients with pulmonary arterial hypertension.”
2011-2017 Chair, Ambrisentan in PAH Associated with Portopulmonary Data and Safety Monitoring Committee: 3 member panel to monitor a 5-site, 30- patient open-label study.
2012-2017 Member, IK-7001-PAH-2011 an International Phase II trial of inhaled nitric oxide in pulmonary arterial hypertension Clinical Events Committee
2012-2017 Member, CONFRONT-PAH Data and Safety Monitoring Committee: A phase 4, randomized, multicenter study of inhaled treprostinil in treatment-naïve pulmonary arterial hypertension patients starting on tadalafil.
2014-2017 Chair, Data and Safety Monitoring Committee for VITA trial “Vascular interventions/Innovations and Therapeutic Advances), an NIH multicenter trial to explore the feasibility of using combined modalities to test the safety of CardioMEMS device in pulmonary arterial hypertension patients.
2016-2020 Member, CATALYST Trial Data Safety Monitoring Committee: 5 member panel to monitor the international trial of 200 patients, ”A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.”
2017-2021 Member, SHOCK trial Data Safety Monitoring Committee: A 4 member panel to monitor pilot study at University of Chicago. Hypothermia pilot.
Kheyfets VO, Sweatt AJ, Gomberg-Maitland M, Ivy DD, Condliffe RL, Kiely DG, Lawrie A, Maron BA, Zamanian RT, Stenmark KR. Computational platform for doctor-AI cooperation in PAH prognostication: a pilot study. Eur Resp J Open Res. 2023 Feb 6;9(1):00484-2022. Doi: 10. 1183/23120541.00484-2022. eCollection 2023 Jan. PMID:36041750.
El-Kersh K, Zhao C, Elliott G, Farber HW, Gomberg-Maitland M, Slelej M, Garcia-Ferrer J, Benza R. Derivation of a risk score (Registry to Evaluate Early and Long-term pulmonary arterial hypertension disease management with echocardiography based on echocardiographic parameters of patients with pulmonary arterial hypertension. Chest. 2023 Jan9: S00012-3692(23)0035-1, PMID:3664897.
Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Grünig E, Kope? G, Meyer G, Olsson KM, Rosenkranz S, Xu Y, Miller B, Fowler M, Butler J, Koglin J, de Oliveira Pena J, Humbert M; STELLAR Trial Investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023 Apr 20;388(16):1478-1490. doi: 10.1056/NEJMoa2213558. Epub 2023 Mar 6. PMID:?36877098?
Weatherald J, Boucly A, Peters A, Montani D, Prasad K, Psotka MA, Zannad F, Gomberg-Maitland M, Mclaughlin V, Simonneau G, Humbert M. Evolving landscape of pulmonary arterial hypertension and redesigning pulmonary arterial hypertension clinical trials task force for the 18th Global Cardiovascular Clinical Trialists Forum. Lancet. 2022 Nov 26;400(10366): 1884-1898. PMID: 36436527
Ryan JJ, Gomberg-Maitland M. Right Heart Catheterization-To Do or Not to Do? Introducing a New Diagnostic Algorithm. JAHA. 2022 Sep 5 11(27):e026589.
Humbert M, McLaughlin VV, Gibbs SJ, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman A, Ghofrani HA, Escribano Subias P, Feldman J, Meyer G, Monani D, Olsson K, Solaiappan M, de Oliveria Pena J, Badesh DB. PULSAR Open-label extension: Safety and efficacy of sotatercept for pulmonary arterial hypertension. Eur Respir J. 2023 Jan 6;61(1):2201347. Epub 2022 Aug 30. PMID:?36041750
Benza RL, Gomberg-Maitland M, Farber HW, Vizza CD, Broderick M, Holdstock L, Nelsen AC, Rao Y, White R.J. Contemporary risk scores predict clinical worsening in pulmonary arterial hypertension- An analysis of FREEDOM-EV. J Heart Lung Transplant. 2022 Nov;4(11):1572-1580. Epub 2022 Aug15.PMID:36117055
Vizza CD, Lang IM, Badagliacca R, Benza RL, Rosenkranz S, White RJ, Adir Y, Andreawssen AK, Balasubramanian V, Bartolome S, Blanco I, Bourge RC, Carlesen C, Conde Camacho RE, D’Alto M, Farber HW, Frantz RP, Ford HJ, GhioS, Gomberg-Maitland M, Naeije R, Orfanos SE, Oudiz RJ, Perrone SV, Shlobin OA, Simon MA, Torres F, Wang KY, Yacoub MH, Liu Y, Golden G, Matsubara H. Aggressive afterload lowering to improve the RV: A new target for medical therapy in PAH? Am J Respir Crit Care Med. 2022 Apr 1;205(7):751-760. PMID: 34905704.
Psotka MA, Thomeas V, Gamazon ER, Hirota T, Tomomitsu H, Friedman PN, Konkashbaev A, Kubo M, Nakamura Y, Ratain MJ, Benza RL, Cox NJ, Gomberg-Maitland M, Maitland ML. Two polymorphic gene loci associate with treprostinil dose in humans with pulmonary arterial hypertension. Pharmacogenetics and Genomics. 2022 Jun 1:32(4):144-151. Epub 2022 Apr 7. PMID: 35383711
Humbert M, McLaughlin V, Gibbs SR, Gomberg-Maitland et al. for the Pulsar Investigators. Sotatercept for the treatment of pulmonary arterial hypertension. NEJM. 2021;384:12014-15. PMID: 33789009
Benza RL, Gomberg-Maitland M, Elliott G, Farber HWA, Foreman AJ, Frost AE, McGoon MD, Pasta DJ, Selej M, Burger C, Frantz RP. An update of the risk score calculator in pulmonary arterial hypertension patients from the registry to evaluate early and long-term PAH disease management (REVEAL). Chest. 2019 Feb 14 (epub)
Sitbon O, Gomberg-Maitland M, Granton J, Lewis MI, Mathai SC, Rainisio M, Stockbridge NL, Wilkins MR, Zamanian RT, Rubin LJ. Clinical trial design and new therapies for pulmonary arterial hypertension. Eur Resp J. 2019 Jan 24;53(1) pii:1801908. Dec. 13. (epub) PMID: 30545975
Simon M, Gomberg-Maitland M, Oudiz R, Rischard F, Elinoff JM, Grigorian B, Schmid A, Hoe S, Desai N, Gladwin M. Patients with severe pulmonary arterial hypertension treated with ABI-009, nab-Sirolimus, an mTOR inhibitor: Interim results from a phase 1 clinical trial. American College of Cardiology, 2019, New Orleans, LA, poster presentation.
Psotka MA, Thomeas-McEwing V, Gamazon ER, Hirota T, Friedman PN, Konkashbaev A, Kubo M, Nakamura Y, Ratain MJ, Benza RL, Cox NJ, Gomberg-Maitland M, Maitland ML. Two polymorphic gene loci associated with treprostinil dose in pulmonary arterial hypertension. International Society of Heart and Lung Transplant, 2019, Orlando, FL, oral presentation.
Simon M, Gomberg-Maitland M, Oudiz R, Rischard F, Elinoff JM, Grigorian B, Schmid A, Hoe S, Desai N, Gladwin M. Patients with severe pulmonary arterial hypertension treated with ABI-009, nab-Sirolimus, an mTOR inhibitor: Interim results from a phase 1 clinical trial. International Society of Heart and Lung Transplant, 2019, Orlando, FL, oral presentation.
Parikh KS, Sharma K, Fiuzat M, Surks HK, George JT, Hoarpour N, Depre C, Desvigne-Nickens P, Nkulikiyinka R, Lewis GD, Gomberg-Maitland M, O’Conner CM, Sockbridge N, Califf RM, Konstam MA, Januzzi JL Jr, Solomon SD, Borlaug BA, Shah SJ, Medfield MM, Felker GM. Heart failure with preserved ejection fraction expert panel report: Current controversies and implications for clinical trails. Jacc Heart Fail. 2018 Aug;6(8):619-632. PMID: 30071950
Chin KM, Gomberg-Maitland M, Channick RN, Cuttica MJ, Fisher A, Frantz RP, Hunsche E, Kleinman L, McConnell JW, McLaughlin VV, Miller CE, Zamanian RT, Zastrow M, Badesch DB. Psychometric validation of the pulmonary arterial hypertension-symptoms and impact (PAH-SYMPACT) questionnaire: Results of the SYMPHONY Trial. Chest 2018 Oct; 154(4):848-861. Epub 2018 Apr 26. PMID: 29705220
D Franco-Palacios JA, King CS, Gomberg-Maitland M. A 70-year old woman presenting with diarrhea and in-hospital cardiac arrest. Chest 2018 Jan;153(1):e5-e8. PMID:29307435.
Chung L, Fairchild RM, Furst DE, Li S, Alkassab F, Bolster MB, Csuka ME, Derk CT, Domsic RT, Fischer A, Frech T, Gomberg-Maitland M, Gordon JK, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TA, Molitor JA, Preston IR, Schiou E, Shapiro L, Hant F, Silver R, Simms R, Varga J, Steen VD, Zamanian RT. Clin Exp Rheumatol. 2016 Nov 10 (epub) PMID 27908301
Medveodofsky D, Aronson D, Gomberg-Maitland M, Thomeas V, Rich S, Spencer K, Mor-Avi V, Addetia K, Lang R.M, Shiran A. Tricuspid regurgitation progression and regression in pulmonary arterial hypertension: implications for right ventricular and tricuspid valve apparatus geometry and patients outcome. Eur Heart J Cardiovasc Imaging 2017; 18(1):86-94.
Waxman AB, McElderry HT, Gomberg-Maitland M, Burke MC, Ross EL, Bersohn MM, Tarver JH, Zwicke DL, Feldman J, Chakinala MM, Frantz RP, Torres F, Li P,Morris M, Peterson L, Bourge RC. Totally implantable intravenous treprostinil therapy in pulmonary hypertension: Assessment of the implantable procedure. Chest 2017 ; 152(6):1128-1134. June 3 (epub) PMID 2858617
Gomberg-Maitland M, Souza R. Uncovering small secrets in big data sets: How math can identify biology in rare conditions (pediatric pulmonary hypertension). Circ Res. 2017 Aug 4; 121(4):317-319.
Twiss J, McKenna SP, Graham J, Swetz K, Sloan J, Gomberg-Maitland M. Applying Rasch analysis to evaluate measurement equivalence of different administration formats of the Activity Limitation scale of the Cambridge Pulmonary Hypertension Review (CAMPHOR). Health Qual Life Outcomes. 2016 Apr9;14: 57. PMID: 27062133
Bourge RC, Waxman AB, Gomberg-Maitland M, Shapiro SM, Tarver JH, Zwicke DL, Feldman JP, Chakinala MM, Frantz RP, Torres F, Cerkvenik J, Morris M, Thalin M, Peterson L, Rubin LJ. Treprostinil administered to treat pulmonary artery hypertension using a fully implantable programmable intravascular delivery system: Results of the DelIVery for PAH Trial. Chest; 2016 Jul;150(1):27-34. Epub 2016 Jan13. PMID: 27396777.
Twiss J, McKenna Sp, Graham J, Swetz K, Sloan J, Gomberg-Maitland M. Health Qual Life Outcomes. 2016 Apr 9;14(1):57. PMID: 27062133
Medvedofsky D, Ahronson D, Gomberg-Maitland M, Thomeas V, Rich S, Spencer K, Mor-Avi V, Addetia K, Lang RM, Shiran A. Tricuspid regurgitation progression and regression in pulmonary arterial hypertension: Implications for right ventricular and tricuspid valve apparatus geometry and patients outcome. Eur Heart J Cardiovasc Imaging. 2016 Feb 11 (epub); PMID: 26873457.
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, Ghofrani HA, Hoeper MM, Lange IM, Preiss R, Rubin LJ, DiScala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV, Williams PG, Beghetti M, COrris P, Pepke-Zaba J, Souza R, DeMets DL, Gomberg-Maitland M, Greenberg BH, Schulman S, Douketis J: GRIPHON Investigators. N Engl J Med. 2015 Dec 24; 373(26): 2522-33. PMID 26699168.
Bonham CA, Oldham JM, Gomberg-Maitland M, Vij R. Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: a retrospective case series. Chest 2015 Oct; 148(4):1055-62. PMID: 26437815
Medriatta A, Addetia K, Medvedofsky D, Gomberg-Maitland M, Mor-Avi V, Lang RM. Echocardiographic diagnosis of acute pulmonary embolism in patients with McConnell’s sign. Echocardiography. 2015 Dec 15. (epub) PMID: 2666928
Gomberg-Maitland M, Schilz R, Mediratta A, Addetia K, Coslet S, Thomeas V, Gillies H, Oudiz RJ. Phase 1 safety study of ranolazine in pulmonary arterial hypertension. Pulm Circ. 2015 Dec;5(4):691-700. PMID: 26697176
Altmayer SP, Patel AR, Addetia K, Gomberg-Maitland M, Forfia PR, Han Y. Cardiac MRI right ventricle/left ventricle (RV/LV) volume ration improves detection of RV enlargement. J Magn Reson Imaging. 2016 Jun; 43(6): 1379-85. Epub 2015 Dec 9. PMID: 26646199
Benza RL, Gomberg-Maitland M, Demarco T, Frost A, Torbicki A, Langleben D, Pulido T, Correa-Jacque P, Passineau MJ, Wiener HW, Tiwari HK. ET-1 pathway polymorphisms effect outcome in pulmonary arterial hypertension. Am J Respir Critical Care Med. 2015 Dec 1; 192(11): 1345-54. Aug 7 (epub). PMID: 26252367
Provencher S, Parchuru P, Spezzi A, Waterhouse B, Gomberg-Maitland M on behalf of the pH12 Flolan reformulation study group. Quality of life, safety and efficacy profile of thermostable flolan in pulmonary arterial hypertension. PLOS ONE 2015 Mar 20; 10(3): e0120657. PMID: 25793960
Jiang R, Ai Zi-Sheng, Zhang R, Jiang X, Liu D, Yuan P, Zhao, Q-H, He J, Peng, F-H, Gomberg-Maitland M, Jing Z-C. Intravenous fasudil improves mortality in acute right heart failure. Hyperns Res. 2015. (epub Mar 19) PMID: 25787034
Fischer A, Swirgis JJ, Bolster MB, Chung L, Csuka ME, Domsic R, Frech t, Hinchcliff M, Hsu V, Hummers LK, Gomberg-Maitland M, Mathai SC, Simms R, Steen VD. Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac hemodynamic parameters. Clin Exp Rheumatol 2014 Nov-Dec; 32(6 Suppl 86): S109-114. Epub 2014 Nov 4. PMID: 25372796
Thenappan T, Samit RM, Duval S, Glassner C, Gomberg-Maitland M. Beta-blocker therapy is not associated with adverse outcomes in patients with pulmonary arterial hypertension: A propensity score analysis. Circ Heart Fail. 2014 Nov; 7(6): 903-910. Epub 2014 Oct 2. PMID: 25277998
Freed BH, Tsang W, Patel AR, Weinert L, Yamat M, Vicedo BM, Dill K, Mor-Avi V, Gomberg-Maitland M, Lang RM. Right ventricular strain in pulmonary arterial hypertension: A 2D echocardiography and cardiac magnetic resonance study. Echocardiography. 2014: Epub June 28. PMID: 24975738
Corson N, Armato SG, Labby ZE, Straus C, Starkey A, Gomberg-Maitland M. CT-based pulmonary artery measurements for the assessment of pulmonary hypertension. Acad Radiol. 2014 Apr; 21(4): 523-30. PMID: 24594422.
Addetia K, Bhave N, Tabit C, Gomberg-Maitland M, Freed B, Dill K, Lang R, Mor-Avi V, Patel AR. Sample size and cost analysis for pulmonary arterial hypertension drug trials using imaging-based right ventricular size and function endpoints. Circ Cardiovascular Imaging. 2014 Jan; 7(1): 115-24. Epub 2013 Nov 5. PMID: 24192452
Gomberg-Maitland M, Glassner-Kolmin C, Watson S, Frantz R, Park M, Frost A, Benza RL, Torres F. Survival in pulmonary hypertension patients awaiting lung transplant. J Heart Lung Transplant. 2013 Dec;32(12): 1179-86. Epub 2013 Sep 25. PMID: 24074527
Chung L, Domsic RT, Lingala B, Alkassab F, Bolster M, Csuka ME, Derk C, Fischer A, Frech T, Furst DE, Gomberg-Maitland M, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TA Jr, Molitor JA, Preston IR, Schiopu E, Shapiro L, Silver R, Simms R, Varga J, Gordon JK, Steen VD. Survival and predictors of mortality in systemic sclerosis associated pulmonary arterial hypertension: Outcomes from the PHAROS registry. Arthritis Care Res. 2013 Aug 27. (Epub).
Thomas I, Glassner-Kolmin C, Gomberg-Maitland M. Long-term effects of continuous prostacyclin therapy in adults with pulmonary hypertension associated with congenital heart disease. Int J Cardiol. 2013 Oct 9; 168(4): 4117-21. (Epub 2013 July 25). PMID:23983198.
Benza RL, Tapson VF, Gomberg-Maitland M, Poms A, Barst RJ, McLaughlin VV. One-year experience with intravenous treprostinil for pulmonary arterial hypertension patients: An update of the 12-week prospective, multicenter, open-label uncontrolled trial. J Heart Lung Transplant 2013 Sep; 32(9): 889-96.
Bhave NM, Patel AR, Weinert L, Yamat M, Freed BH, Mor-Avi V, Gomberg-Maitland M, Lang R. Three-dimensional modeling of the right ventricle from two-dimensional transthoracic echocardiographic images: Utility of knowledge-based reconstruction in pulmonary arterial hypertension. J Am Soc Echocardiogr 2013; 26: 860-867. Epub June 12.
Deano RC, Rubenfire M, Frost A, Glassner-Kolmin C, Visovattu S, McLaughlin VV, Gomberg-Maitland M. Referral of patients with pulmonary hypertension to tertiary pulmonary hypertension centers: The multicenter RePHerral study. JAMA-Intern Med 2013 May 27;173 (10): 887-893. PMID: 23568223
Meyer S, McLaughlin VV, Seyfarth, H-J, Bull T, Vizza D, Gomberg-Maitland M, Preston I, Barbera J, Hassoun P, Halank M, Jais X, Nickel N, Hoeper MM, Humbert M. Outcome of non-cardiac surgery in patients with pulmonary arterial hypertension: results from an international prospective survey. Eur Resp J 2012 Nov 8 (Epub).
Freed BH, Gomberg-Maitland M, Chandra S, Mor-Avi V, Rich S, Archer SL, Jamison B, Lang RM, Patel AR. Contrast-enhanced cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension. Journal of Cardiovasc Magn Reson. 2012 Feb 1; 14:11.
Agarwal R, Shah SJ, Foreman A, Glassner C, Bartolome SD, Zafdar Z, Coslet SL, Anderson AS, Gomberg-Maitland M. Risk assessment in pulmonary hypertension associated with heart failure and preserved ejection fraction. J Heart Lung Transpl May; 31(5): 467-77. Epub 2012 2012 Jan 4.
Thenappan T, Glassner C, Gomberg-Maitland M. Validation of the pulmonary hypertension connection equation for survival prediction in pulmonary arterial hypertension. Chest 2012 March; 141(3): 642-650. Epub 2011 Sep 1.
Hsu C-S, Agarwal R, Foreman A, Benza R, Frantz RP, Gomberg-Maitland M. Treadmill testing aids prediction of prognosis in pulmonary arterial hypertension. Am Heart J. 2011 Dec; 162(6): 1011-7. Epub 2011 Nov 8.
Zhang Z-N, Jiang X, Zhang R, Li X-L, Wu B-X, Zhao Q-H, Wang Y, Dai L-Z, Pan L, Gomberg-Maitland M, Jing Z-C. Oral sildenafil therapy for eisenmenger syndrome: A prospective, open-label, multicenter study. Heart 2011 Nov; 97(22): 1876-81. Epub 2011 Sep 21.
Sun P-Y, Jiang X, Gomberg-Maitland M, Dai L-Z, Zhao Q-H, Jing Z-C. Prolonged QRS duration: A new predictor of adverse outcome in idiopathic pulmonary arterial hypertension. Chest 2012 Feb; 141(2): 374-380. Epub 2011 Jul 21. PMID: 21778258
Sciancalepore MA, Maffessanti F, Patel AR, Gomberg-Maitland M, Chandra S, Freed BH, Caiani EG, Lang RM, Mor-Avi, V. Three-Dimensional analysis of septal shape from cardiac magnetic resonance images for the evaluation of patients with pulmonary hypertension. Int J Cardiovasc Imaging. 2012 Jun; 28:1073-1085. Epub 2011 June 22. PMID: 21695484
Rich J, Glassner C, Coslet S, McDevit S, Aronson C, Wade M, Gomberg-Maitland M. The effect of diluent pH on infection rates in patients receiving IV treprostinil for pulmonary hypertension. 2011, CHEST 2011, June 9. Epub. PMID: 21659437
Industry Relationships and Collaborations
This faculty member (or a member of their immediate family) has reported a financial interest with the health care related companies listed below. These relations have been reported to the University and, when appropriate, management plans are in place to address potential conflicts.
- Acceleron Pharma